

Patrizia Chiusolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3044153/publications.pdf>

Version: 2024-02-01

253
papers

6,493
citations

81743

39
h-index

82410

72
g-index

262
all docs

262
docs citations

262
times ranked

7550
citing authors

#	ARTICLE	IF	CITATIONS
1	The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin Mutation. <i>New England Journal of Medicine</i> , 1999, 341, 801-806.	13.9	467
2	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. <i>Blood</i> , 1998, 91, 3562-3565.	0.6	222
3	Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005, 105, 4820-4827.	0.6	221
4	Epidemiology of Factor V Leiden: Clinical Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 367-379.	1.5	207
5	The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1985-1992.	1.9	206
6	Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 708-714.	1.9	203
7	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	0.6	192
8	Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1293-1301.	2.0	165
9	Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009, 58, 299-307.	1.7	144
10	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	5.1	143
11	Infections by carbapenem-resistant <i>Klebsiella pneumoniae</i> in SCT recipients: a nationwide retrospective survey from Italy. <i>Bone Marrow Transplantation</i> , 2015, 50, 282-288.	1.3	142
12	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
13	The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. <i>Leukemia</i> , 2007, 21, 110-120.	3.3	132
14	Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 114, 1437-1444.	0.6	131
15	Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. <i>Annals of Oncology</i> , 2002, 13, 1915-1918.	0.6	125
16	Genetic Risk Factors for Superficial Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1215-1217.	1.8	121
17	Negative prognostic value of glutathione S-transferase(GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	0.6	110
18	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2677-2682.	0.2	88

#	ARTICLE	IF	CITATIONS
19	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
20	Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients. <i>British Journal of Haematology</i> , 2020, 191, 207-211.	1.2	84
21	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. <i>Leukemia</i> , 2019, 33, 1173-1183.	3.3	83
22	The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. <i>British Journal of Haematology</i> , 2001, 113, 630-635.	1.2	80
23	Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. <i>Transfusion</i> , 2014, 54, 2514-2522.	0.8	75
24	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
25	Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. <i>British Journal of Haematology</i> , 1998, 103, 871-876.	1.2	60
26	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	1.7	54
27	MTHFR polymorphisms influence on outcome and toxicity in acute lymphoblastic leukemia patients. <i>Leukemia Research</i> , 2007, 31, 1669-1674.	0.4	53
28	THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016025.	0.5	53
29	Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia. <i>Experimental Hematology</i> , 2001, 29, 670-676.	0.2	51
30	Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. <i>Haematologica</i> , 2009, 94, 733-737.	1.7	51
31	Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden, MTHFR C677T) in essential thrombocythemia. <i>Journal of Haematology</i> , 1999, 106, 564-568.	1.2	50
32	Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation. <i>Supportive Care in Cancer</i> , 2013, 21, 531-535.	1.0	50
33	Hyperleukocytosis and leukostasis: management of a medical emergency. <i>Expert Review of Hematology</i> , 2017, 10, 147-154.	1.0	49
34	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1243-1249.	2.0	49
35	JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. <i>Blood Cancer Journal</i> , 2021, 11, 199.	2.8	47
36	Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. <i>Bone Marrow Transplantation</i> , 2007, 40, 245-249.	1.3	46

#	ARTICLE	IF	CITATIONS
37	Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. <i>Cytotherapy</i> , 2003, 5, 19-30.	0.3	42
38	Secondary Ph+ acute lymphoblastic leukemia after temozolomide. <i>Annals of Hematology</i> , 2005, 84, 760-762.	0.8	42
39	Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis. <i>American Journal of Hematology</i> , 2009, 84, 381-382.	2.0	42
40	Successful Treatment with Caspofungin of Hepatosplenic Candidiasis Resistant to Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2002, 35, 1135-1136.	2.9	41
41	Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. <i>Haematologica</i> , 2004, 89, 139-44.	1.7	41
42	The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 691-696.	1.1	40
43	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. <i>Transplantation</i> , 2016, 100, e147-e155.	0.5	40
44	Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007, 82, 787-791.	2.0	39
45	Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. <i>European Heart Journal</i> , 2002, 23, 26-30.	1.0	38
46	Highly active antiretroviral therapy and allogeneic CD34+ peripheral blood progenitor cells transplantation in an HIV/HCV coinfecting patient with acute myeloid leukemia. <i>Experimental Hematology</i> , 2002, 30, 279-284.	0.2	36
47	Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 499-503.	0.5	33
48	Fine granularity clustering for large scale placement problems. , 2003, , .		33
49	Hormonal replacement therapy after stem cell transplantation. <i>Maturitas</i> , 2004, 49, 327-333.	1.0	33
50	Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1998, 21, 821-823.	1.3	32
51	JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. <i>American Journal of Hematology</i> , 2011, 86, 526-528.	2.0	31
52	Early diagnosis followed by front-line autologous peripheral blood stem cell transplantation for patients affected by POEMS syndrome. <i>Leukemia Research</i> , 2008, 32, 1309-1312.	0.4	30
53	The role of HLA-G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2012, 47, 120-124.	1.3	30
54	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020, 4, 3900-3912.	2.5	30

#	ARTICLE	IF	CITATIONS
55	Optimal timing of G-CSF administration after CD34+immunoselected peripheral blood progenitor cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 1245-1250.	1.3	28
56	Immune reconstitution after autologous peripheral blood progenitor cell transplantation. <i>Experimental Hematology</i> , 2001, 29, 1503-1516.	0.2	28
57	Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2009, 84, 126-127.	2.0	28
58	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 181-185.	0.6	28
59	The Growth of Primary Low-Grade B-Cell Gastric Lymphoma Is Sustained by <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 285-287.	0.6	27
60	Report of a novel kindred with antithrombin heparin-binding site variant (47 Arg to His): Demand for an automated progressive antithrombin assay to detect molecular variants with low thrombotic risk. <i>Thrombosis and Haemostasis</i> , 2007, 98, 695-697.	1.8	27
61	The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. <i>Pharmacogenomics Journal</i> , 2014, 14, 115-119.	0.9	27
62	Steroid treatment of acute graft- <i>versus</i> -host disease grade I: a randomized trial. <i>Haematologica</i> , 2017, 102, 2125-2133.	1.7	27
63	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing Tëcell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (<sc>ALWP</sc>) of the European Society for Blood and Marrow Transplantation (<sc>EBMT</sc>). <i>British Journal of Haematology</i> , 2018, 183, 411-420.	1.2	27
64	The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. <i>British Journal of Haematology</i> , 2001, 114, 150-154.	1.2	24
65	Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin. <i>Leukemia</i> , 2007, 21, 1821-1824.	3.3	24
66	Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stemëcell transplantation. <i>American Journal of Hematology</i> , 2012, 87, 641-642.	2.0	24
67	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1915-1922.	2.0	24
68	Therapy-related MDS and AML in acute promyelocytic leukemia. <i>Blood</i> , 2002, 100, 1928-1930.	0.6	22
69	Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 4443-4444.	0.6	22
70	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. <i>Leukemia</i> , 2013, 27, 982-985.	3.3	22
71	Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 708-712.	1.3	22
72	Immune reconstitution after autologous selected peripheral blood progenitor cell transplantation: comparison of two CD34+ cell-selection systems. <i>Transfusion</i> , 2001, 41, 783-789.	0.8	21

#	ARTICLE	IF	CITATIONS
73	Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CBâ€rIP study. <i>British Journal of Haematology</i> , 2020, 191, 263-268.	1.2	21
74	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibodyâ€”Beigelomab. <i>Bone Marrow Transplantation</i> , 2020, 55, 1580-1587.	1.3	21
75	Screening of JAK2 V617F mutation in multiple myeloma. <i>Leukemia</i> , 2006, 20, 1912-1913.	3.3	20
76	Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 253-256.	0.4	20
77	Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2007, 21, 1819-1821.	3.3	20
78	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2017, 52, 955-961.	1.3	20
79	Morganella morganii Pericarditis After Resolvent Splenectomy for Immune Pancytopenia Following Allogeneic Bone Marrow Transplantation for Acute Lymphoblastic Leukemia. <i>Clinical Infectious Diseases</i> , 1995, 21, 1052-1053.	2.9	19
80	Prospective Evaluation of Epsteinâ€”Barr Virus Reactivation After Stem Cell Transplantation: Association with Monoclonal Gammopathy. <i>Journal of Clinical Immunology</i> , 2010, 30, 894-902.	2.0	19
81	Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2011, 35, 422-423.	0.4	19
82	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 698-703.	2.0	19
83	Treatment and prophylaxis of hypermenorrhea with leuprorelin in premenopausal women affected by acute leukemia at diagnosis. , 1996, 51, 248-249.		18
84	Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. <i>Transfusion</i> , 2005, 45, 643-645.	0.8	18
85	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1814-1822.	2.0	18
86	Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinicalâ€”biological features of multiple myeloma. <i>Annals of Hematology</i> , 2006, 85, 474-477.	0.8	17
87	Salivary Proteomic Analysis and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 888-892.	2.0	17
88	Prevalence of the 677C to T Mutation in the Methylenetetrahydrofolate Reductase Gene in Italian Patients with Venous Thrombotic Disease. <i>Thrombosis and Haemostasis</i> , 1998, 79, 686-687.	1.8	16
89	Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. <i>International Journal of Hematology</i> , 2021, 114, 228-234.	0.7	16
90	Autologous Graft-Versus-Host Disease after CD34+-Purified Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 375-379.	1.8	15

#	ARTICLE	IF	CITATIONS
91	EXTRAMEDULLARY INVOLVEMENT IN ACUTE MYELOID LEUKEMIA. A SINGLE CENTER TEN YEARS EXPERIENCE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021030.	0.5	15
92	Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. <i>Haematologica</i> , 2022, 107, 996-999.	1.7	15
93	Highly fluorescent reticulocyte count predicts haemopoietic recovery after immunosuppression for severe aplastic anaemia. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 387-389.	0.2	14
94	High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. <i>Hepatology</i> , 2007, 45, 831-832.	3.6	14
95	The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1121.	1.8	14
96	Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2009, 144, 965-967.	1.2	14
97	Role of flow cytometric immunophenotyping in prediction of BCR/ABL1 gene rearrangement in adult acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 468-476.	0.7	14
98	Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. <i>American Journal of Hematology</i> , 2021, 96, 234-240.	2.0	14
99	Second haploidentical stem cell transplantation for primary graft failure. <i>Bone Marrow Transplantation</i> , 2021, 56, 1291-1296.	1.3	14
100	Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. <i>Cytotherapy</i> , 2021, 23, 635-640.	0.3	14
101	Prevalence of the Factor II G20210A Mutation in Symptomatic Patients with Inherited Thrombophilia. <i>Thrombosis and Haemostasis</i> , 1998, 80, 342-343.	1.8	14
102	A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19. <i>Scientific Reports</i> , 2021, 11, 21136.	1.6	14
103	Incidence of Sepsis After Peripheral Blood Progenitor Cells Transplantation: Analysis of 86 Consecutive Hemato Oncological Patients. <i>Leukemia and Lymphoma</i> , 1998, 30, 193-197.	0.6	13
104	Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. <i>Leukemia</i> , 2007, 21, 2552-2554.	3.3	13
105	Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. <i>Annals of Hematology</i> , 2008, 87, 891-898.	0.8	13
106	Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome. <i>Annals of Hematology</i> , 2011, 90, 59-65.	0.8	13
107	GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 96.e1-96.e11.	0.6	13
108	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. <i>American Journal of Hematology</i> , 2020, 95, 749-758.	2.0	12

#	ARTICLE	IF	CITATIONS
109	Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease. <i>Bone Marrow Transplantation</i> , 1998, 22, 823-825.	1.3	11
110	Mitoxantrone, carboplatin, cytosine arabinoside, and methylprednisolone followed by autologous peripheral blood stem cell transplantation. <i>Cancer</i> , 2006, 106, 859-866.	2.0	11
111	Low-Dose Valganciclovir as Preemptive Therapy for Cytomegalovirus Infection Occurring in Allogeneic Stem Cell Transplant Recipients. <i>Acta Haematologica</i> , 2010, 123, 230-234.	0.7	11
112	Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. <i>Bone Marrow Transplantation</i> , 2020, 55, 2114-2120.	1.3	11
113	Hepatic Vein Thrombosis in a Patient with Mutant Prothrombin 20210A Allele. <i>Thrombosis and Haemostasis</i> , 1998, 80, 519-519.	1.8	11
114	Immune Recovery of Lymphocyte Subsets 6 Years after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoproliferative Diseases. A Comparison between NHL, HD and MM in Group of 149 Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 2063-2070.	0.6	10
115	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. <i>Leukemia and Lymphoma</i> , 2016, 57, 2429-2431.	0.6	10
116	Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 929-933.	0.8	10
117	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.	0.6	10
118	Unrelated cord blood transplantation and post-transplant cyclophosphamide. <i>Haematologica</i> , 2019, 104, e77-e78.	1.7	10
119	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. <i>Cytotherapy</i> , 2020, 22, 158-165.	0.3	10
120	Reliability of Leukostasis Grading Score to Identify High Risk Patients with Hyperleukocytic Leukemia. <i>Blood</i> , 2008, 112, 2979-2979.	0.6	10
121	Hormonal Therapy After Stem Cell Transplantation and the Risk of Venous Occlusive Disease. <i>Blood</i> , 1999, 93, 3154-3154.	0.6	9
122	Glycoprotein Ia C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up. <i>British Heart Journal</i> , 2004, 90, 567-569.	2.2	9
123	Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease. <i>Vox Sanguinis</i> , 2016, 110, 189-192.	0.7	9
124	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018005.	0.5	9
125	Inline and offline extracorporeal photopheresis: Device performance, cell yields and clinical response. <i>Journal of Clinical Apheresis</i> , 2021, 36, 118-126.	0.7	9
126	Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. <i>Frontiers in Immunology</i> , 2021, 12, 637512.	2.2	9

#	ARTICLE	IF	CITATIONS
127	Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2014, 124, 3880-3880.	0.6	9
128	Gut Microbiome Changes after Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1953-1953.	0.6	9
129	Inappropriate antidiuretic hormone secretion after high-dose thiotepa. <i>Bone Marrow Transplantation</i> , 1999, 24, 571-572.	1.3	8
130	MiCMA: An alternative treatment for refractory or recurrent Hodgkin's disease. <i>Annals of Oncology</i> , 2000, 11, 867-871.	0.6	8
131	Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. <i>Clinical Transplantation</i> , 2008, 22, 837-841.	0.8	8
132	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. <i>Annals of Hematology</i> , 2020, 99, 867-875.	0.8	8
133	Thiotepa+busulfan+fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	1.3	8
134	Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2021, 127, 2507-2514.	2.0	8
135	Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. <i>Haematologica</i> , 2002, 87, 59-66.	1.7	8
136	Secondary myelodysplastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria. <i>Bone Marrow Transplantation</i> , 2000, 26, 241-242.	1.3	7
137	Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2005, 19, 153-154.	3.3	7
138	Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 2054-2057.	0.6	7
139	Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2012, 47, 872-873.	1.3	7
140	Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014, 55, 2958-2960.	0.6	7
141	Pre-Exposure to Defibrotide Prevents Endothelial Cell Activation by Lipopolysaccharide: An Ingenuity Pathway Analysis. <i>Frontiers in Immunology</i> , 2020, 11, 585519.	2.2	7
142	Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: Case reports and literature review. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29044.	0.8	7
143	A Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen, Following Unmanipulated Haploidentical Bone Marrow Transplantation, for Acute Myeloid Leukemia: A Multicenter Study. <i>Blood</i> , 2016, 128, 1234-1234.	0.6	7
144	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. <i>Bone Marrow Transplantation</i> , 2022, 57, 949-958.	1.3	7

#	ARTICLE	IF	CITATIONS
145	Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. <i>Leukemia</i> , 2006, 20, 2198-2199.	3.3	6
146	Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of preâ€transplant therapy. <i>Clinical Transplantation</i> , 2008, 22, 191-199.	0.8	6
147	MTHFR Polymorphisms Involved in Vitamin B12 Deficiency Associated with Atrophic Gastritis. <i>Biochemical Genetics</i> , 2009, 47, 645-650.	0.8	6
148	Clinical Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015025.	0.5	6
149	Mononuclear cell collection for extracorporeal photopheresis: Concentrate characteristics for offâ€line UVâ€A irradiation procedure. <i>Journal of Clinical Apheresis</i> , 2018, 33, 217-221.	0.7	6
150	Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome. <i>Hematological Oncology</i> , 2018, 36, 392-398.	0.8	6
151	Inline extracorporeal photopheresis: evaluation of cell collection efficiency. <i>Transfusion</i> , 2019, 59, 3714-3720.	0.8	6
152	SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102881.	0.5	6
153	Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience. <i>Frontiers in Oncology</i> , 2021, 11, 614721.	1.3	6
154	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. <i>Blood</i> , 1998, 91, 3562-3565.	0.6	6
155	Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants. <i>Bone Marrow Transplantation</i> , 2022, 57, 532-537.	1.3	6
156	COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. <i>Haematologica</i> , 2022, 107, 1955-1959.	1.7	6
157	Early viral complications after autologous CD34-selected peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2000, 26, 587-588.	1.3	5
158	Glutamine parenteral supplementation in stem cell transplant. <i>Bone Marrow Transplantation</i> , 2004, 33, 455-455.	1.3	5
159	Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. <i>Leukemia</i> , 2004, 18, 1824-1830.	3.3	5
160	Twenty years of unrestricted hematopoietic stem cell collection and storage: impact of Joint Accreditation Committee International Society for Cellular Therapy Europe standards implementation on stem cell storage policy and resource utilization. <i>Cytotherapy</i> , 2013, 15, 519-521.	0.3	5
161	Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. <i>Bone Marrow Transplantation</i> , 2018, 53, 1560-1567.	1.3	5
162	â€Secondary chronic myeloid leukemiaâ€™: comparison between patients previously exposed or not to chemo- and/or radiotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3584-3586.	0.6	5

#	ARTICLE	IF	CITATIONS
163	Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2514-2516.	2.0	5
164	Prevalence of Mutated Factor V ARG506 to GLN in Italians. <i>Thrombosis and Haemostasis</i> , 1997, 77, 216-217.	1.8	5
165	Epstein-Barr Virus Related Lymphoproliferations After Stem Cell Transplantation. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009019.	0.5	5
166	Sustained Signaling through the B-Cell Receptor Induces Mcl-1 and Promotes Survival of Chronic Lymphocytic Leukemia B-Cells.. <i>Blood</i> , 2004, 104, 178-178.	0.6	5
167	Molecular and clinical follow-up after stem cell transplantation for multiple myeloma. <i>Annals of Hematology</i> , 2001, 80, 90-95.	0.8	4
168	Kinetics of peg-filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 579-583.	1.3	4
169	Clonal gammopathies and allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 317-317.	1.3	4
170	NEUROLOGIC IMPROVEMENT AFTER PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN POEMS. <i>Neurology</i> , 2009, 73, 1165-1166.	1.5	4
171	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	0.6	4
172	Massive pulmonary embolism at the onset of acute promyelocytic leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016027.	0.5	4
173	Preoperative autologous blood donation in adult bone marrow donors: reappraisal of a single centre experience. <i>Vox Sanguinis</i> , 2019, 114, 762-768.	0.7	4
174	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 406.e1-406.e11.	0.6	4
175	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1842-1849.	1.3	4
176	DAYS ALIVE OUTSIDE HOSPITAL AND RE-ADMISSIONS IN PATIENTS UNDERGOING ALLOGENEIC TRANSPLANTS FROM IDENTICAL SIBLINGS, UNRELATED DONORS OR HAPLOIDENTICAL DONORS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020055.	0.5	4
177	Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. <i>Haematologica</i> , 2021, 106, 3162-3169.	1.7	4
178	Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia. <i>Supportive Care in Cancer</i> , 2022, 30, 4953-4959.	1.0	4
179	Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 837-839.	1.3	4
180	Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM. <i>Annals of Oncology</i> , 2006, 17, 720-721.	0.6	3

#	ARTICLE	IF	CITATIONS
181	Antituberculosis Therapy and Imatinib for Chronic Myeloid Leukemia. <i>Clinical Infectious Diseases</i> , 2006, 43, 1223-1223.	2.9	3
182	Changes in protein serum levels during stem cell transplantation. <i>European Journal of Clinical Investigation</i> , 2017, 47, 711-718.	1.7	3
183	Sudden death of a SARS-CoV-2 patient with NPM1+ acute myeloid leukemia mimicking acute promyelocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 341-342.	0.7	3
184	The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 918.e1-918.e9.	0.6	3
185	Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T). <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021066.	0.5	3
186	Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem. <i>Blood</i> , 2021, 138, 3867-3867.	0.6	3
187	The Hohn catheter in the management of haemopoietic stem cell transplant recipients. <i>European Journal of Cancer Care</i> , 1998, 7, 201-205.	0.7	2
188	Cerebral Vein Thrombosis not Related to Use of Oral Contraceptives in a 7-year-old Child Carrier of the Prothrombin 20210A Allele. <i>Thrombosis and Haemostasis</i> , 1999, 81, 991-992.	1.8	2
189	Non-invasive ventilatory support in the management of respiratory failure after autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 527-527.	1.3	2
190	Persistent immunological changes 55 months after PBPCT. Is the restoration of immune function possible with a longer follow-up?. <i>Bone Marrow Transplantation</i> , 2000, 26, 707-708.	1.3	2
191	Reply to "Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma" by Dr Qin Huang et al. referred to "Screening of JAK2 V617F mutation in multiple myeloma" from Fiorini A et al. published in <i>Leukemia</i> 2006, October 20. <i>Leukemia</i> , 2007, 21, 814-815.	3.3	2
192	ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010026.	0.5	2
193	Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience. <i>Hematological Oncology</i> , 2011, 29, 107-110.	0.8	2
194	High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, E133.	2.0	2
195	Complete Remission Obtained with Azacitidine in a Patient with Concomitant Therapy Related Myeloid Neoplasm and Pulmonary Mucormycosis. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013048.	0.5	2
196	Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. <i>Journal of Clinical Immunology</i> , 2018, 38, 7-9.	2.0	2
197	Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid. <i>Leukemia and Lymphoma</i> , 2019, 60, 1328-1330.	0.6	2
198	Use of DPB1 T cell epitope algorithm among italian transplant centers: A survey on behalf of Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Hla</i> , 2021, 98, 114-121.	0.4	2

#	ARTICLE	IF	CITATIONS
199	ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. <i>Transplantation Direct</i> , 2021, 7, e724.	0.8	2
200	Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation. <i>Supportive Care in Cancer</i> , 2022, 30, 1521-1527.	1.0	2
201	Busulfan Fludarabine (BU-FLU) Compared to Thiotepa Busulfan Fludarabine (TBF) for Allogeneic Transplants in Acute Myeloid Leukemia (AML) or Refractory Anemia with Excess Blasts (RAEB) in Remission. <i>Blood</i> , 2017, 130, 909-909.	0.6	2
202	"Secondary Chronic Myeloid Leukemia": Comparison between Patients Previously Exposed or Not to Chemo and/or Radiotherapy. <i>Blood</i> , 2018, 132, 5437-5437.	0.6	2
203	IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2021, 13, e2021062.	0.5	2
204	Successful "demand" plerixafor for autologous peripheral blood stem cells transplantation for relapsed/refractory germ cell tumors. <i>Journal of Clinical Apheresis</i> , 2021, , .	0.7	2
205	Factor V Leiden and allogeneic bone marrow transplantation: chimerism as a confounding factor in genetic test interpretation. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 401-402.	0.2	1
206	Non-Tunneled Central Venous Catheters in Adult Stem Cell Transplantation Recipients: An Effective Option. <i>Journal of Vascular Access</i> , 2001, 2, 168-174.	0.5	1
207	The association of severe aplastic anaemia with the philadelphia chromosome and the bcr/abl transcript. <i>British Journal of Haematology</i> , 2001, 114, 954-962.	1.2	1
208	Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells in multiple myeloma The issue of safety. <i>Experimental Hematology</i> , 2001, 29, 1-2.	0.2	1
209	The treatment of menorrhagia in female stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2005, 35, 827-827.	1.3	1
210	ABO type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients. <i>Transfusion</i> , 2008, 48, 2645-2646.	0.8	1
211	Chronic Lymphocytic Leukemia With Eyelid Involvement Responding to Alemtuzumab. <i>Journal of Clinical Oncology</i> , 2008, 26, 5299-5301.	0.8	1
212	Simultaneous double mismatched cord blood transplantation in a young patient with secondary myelodysplastic syndrome: Feasibility and complications. <i>Leukemia and Lymphoma</i> , 2008, 49, 821-823.	0.6	1
213	Correlation between paraproteinaemia and viral reactivation after allo-SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 1262-1262.	1.3	1
214	Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. <i>Annals of Nuclear Medicine</i> , 2012, 26, 764-768.	1.2	1
215	Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT. <i>Annals of Hematology</i> , 2020, 99, 207-209.	0.8	1
216	Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Hematological Oncology</i> , 2021, 39, 267-269.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Blood</i> , 2014, 124, 727-727.	0.6	1
218	Isolation, Expansion and Characterization of BM-Mesenchymal Cells (MSCs) in Patients Affected By Chronic Myeloproliferative neoplasm (MPN). <i>Blood</i> , 2014, 124, 5142-5142.	0.6	1
219	Which Is the Best Mobilizing Regimen in POEMS Syndrome? a Retrospective Italian Study of Two Haematological Centres. <i>Blood</i> , 2018, 132, 5692-5692.	0.6	1
220	Hematologic Recovery after Allogeneic Transplantation: Risk Factors and Its IMPACT on Transplant Related Mortality. <i>Blood</i> , 2021, 138, 2867-2867.	0.6	1
221	Cytomegalovirus and Epstein Barr Virus Reactivation after Allogeneic Stem Cell Transplantation in Pre- and Post-Letermovir Era. <i>Blood</i> , 2021, 138, 1782-1782.	0.6	1
222	Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag. <i>Medicina (Lithuania)</i> , 2021, 57, 1326.	0.8	1
223	Successful Second Autologous Stem Cell Transplantation for Late Disease Progression after the First Procedure in POEMS Syndrome. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 2577.	1.3	1
224	The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 2309-2318.	2.5	1
225	Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism related enzymes in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2001, 33, A120.	0.4	0
226	Kinetics of hemopoietic recovery after peripheral blood stem cell transplantation: Impact of stem cell purification and G-CSF. <i>American Journal of Hematology</i> , 2002, 69, 7-14.	2.0	0
227	The Use of Positron Emission Tomography with [18F] 2-Fluoro-d-2-Deoxyglucose (FDG-PET) in Hodgkin and Non-Hodgkin's Lymphoma. <i>Hematology</i> , 2003, 8, 403-408.	0.7	0
228	Circulating hematopoietic progenitor cells after autologous stem cell transplant for hematological malignancies. <i>Leukemia and Lymphoma</i> , 2010, 51, 1135-1138.	0.6	0
229	Outcome of concurrent acute myeloid leukemia and granulocytic sarcoma: three clinical cases and a review of the literature. <i>Comparative Clinical Pathology</i> , 2012, 21, 725-730.	0.3	0
230	Myeloablative Versus Nonmyeloablative Conditioning Regimen in Haploidentical Transplantation: Does It Matter and How Best to Select Between the Two?. , 2018, , 159-171.		0
231	ALL-159: A Retrospective Real-Life Report on Newly Diagnosed Adult Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Treated in Italy - The CAMPUS-ALL Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S162.	0.2	0
232	The Use of Low-Dose Alemtuzumab as Single Agent in the Treatment of Complication in Advanced Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2008, 112, 4212-4212.	0.6	0
233	SDF1 Plasma Levels and CD34+ Cells Recirculation After Autologous Peripheral Blood Stem Cell Transplant.. <i>Blood</i> , 2009, 114, 4571-4571.	0.6	0
234	ROLE of Fecal Calprotectin as BIOMARKER of Gvhd AFTER Allogeneic STEM CELL TRANSPLANTATION. <i>Blood</i> , 2010, 116, 1253-1253.	0.6	0

#	ARTICLE	IF	CITATIONS
235	DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma –Results from an EBMT Non Interventional Prospective Study. Blood, 2010, 116, 2397-2397.	0.6	0
236	In Patient with Chronic Lymphocytic Leukemia the Overall SURVIVAL Is NOT Different WHEN Analysed by Cause of Death, Related or NOT Related to the Disease. Blood, 2012, 120, 4587-4587.	0.6	0
237	Hormonal Therapy After Stem Cell Transplantation and the Risk of Venous Thrombotic Disease. Blood, 1999, 93, 3154-3154.	0.6	0
238	Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood, 2014, 124, 731-731.	0.6	0
239	Granulocyte Transfusions at Appropriate Doses Improve Survival in Hematological Patients with Febrile Neutropenia. Blood, 2015, 126, 3566-3566.	0.6	0
240	the Polymorphisms on Chromosome 9p21 Play a Role in the Risk for Cardiovascular Events in Chronic Myeloid Leukemia Patients?. Blood, 2016, 128, 5100-5100.	0.6	0
241	EARLY Post-Transplant Events , Cost of Admission and Mortality, in Patients Undergoing Allogeneic Transplants from Identical Siblings, Unrelated Donors or Haploidentical Donors. Blood, 2018, 132, 4648-4648.	0.6	0
242	Unmanipulated Haploidentical Marrow Transplantation with a Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen: An Update on 444 Patients. Blood, 2018, 132, 3351-3351.	0.6	0
243	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. Blood, 2018, 132, 4642-4642.	0.6	0
244	Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen. Blood, 2019, 134, 4490-4490.	0.6	0
245	Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY). Blood, 2019, 134, 3332-3332.	0.6	0
246	The Impact of Aminoacid Substitution at Position 116 Class I HLA, in Unrelated Donor Transplants. Blood, 2019, 134, 4620-4620.	0.6	0
247	Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens. Blood, 2019, 134, 1974-1974.	0.6	0
248	ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report. Blood, 2021, 138, 216-216.	0.6	0
249	Triple Post-Transplant Cyclophosphamide (PTCY) Based Gvhd Prophylaxis for HLA Matched or HLA Haploidentical Transplants. Blood, 2021, 138, 4881-4881.	0.6	0
250	Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study. Blood, 2021, 138, 1786-1786.	0.6	0
251	The Impact of Age in Allogeneic Stem Cell Transplantation with Thiotepa Busulfan and Fludarabine (TBF) for Myelofibrosis : A Retrospective Analysis. Blood, 2021, 138, 4858-4858.	0.6	0
252	Similar Molecular Pattern in Therapy Related Acute Myeloid Leukemia in Patients Treated with Purp Inhibitors for Metastatic Ovarian Cancer. Blood, 2020, 136, 40-40.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2022, , .	1.3	0